Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function
- PMID: 17504777
- PMCID: PMC2632374
- DOI: 10.1093/schbul/sbm041
Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function
Abstract
Recognition of the need to treat cognitive deficits in schizophrenia is compelling and well established, with empirical findings and conceptual arguments related to cognitive enhancement appearing regularly in the literature. Cognitive enhancement itself, however, remains at an early stage. Biological approaches have centered on the development of antipsychotic medications that also improve cognition, but the results have so far remained modest. As a way to facilitate the development of cognitive enhancers in schizophrenia, this article focuses on adjunctive pharmacological approaches to antipsychotic medications and highlights the need for systematic explorations of relevant brain mechanisms. While numerous conceptual criteria might be employed to guide the search, we will focus on 4 points that are especially likely to be useful and which have not yet been considered together. First, the discussion will focus on deficits in a particular cognitive domain, verbal declarative memory. Second, we will review the current status of preclinical and clinical efforts to improve declarative memory using antipsychotic medications, which is the main, existing mode of treatment. Third, we will examine an example of an adjunctive intervention-glucose administration-that improves memory in animals and humans, modulates function in brain regions related to verbal declarative memory, and is highly amenable to translational research. Finally, a heuristic model will be outlined to explore how the intervention maps on to the underlying neurobiology of schizophrenia. More generally, the discussion underlines the promise of cognitive improvement in schizophrenia and the need to approach the issue in a programmatic manner.
Figures
Similar articles
-
The cognitive neuroscience of memory function and dysfunction in schizophrenia.Biol Psychiatry. 2008 Jul 1;64(1):18-25. doi: 10.1016/j.biopsych.2008.04.011. Epub 2008 May 21. Biol Psychiatry. 2008. PMID: 18495087 Free PMC article.
-
Schizophrenia and cognitive function.Curr Opin Neurobiol. 2000 Apr;10(2):205-10. doi: 10.1016/s0959-4388(00)00068-4. Curr Opin Neurobiol. 2000. PMID: 10753790 Review.
-
Declarative memory deficits and schizophrenia: problems and prospects.Neurobiol Learn Mem. 2011 Nov;96(4):544-52. doi: 10.1016/j.nlm.2011.04.006. Epub 2011 Apr 20. Neurobiol Learn Mem. 2011. PMID: 21527348 Review.
-
The cognitive neuroscience of working memory: relevance to CNTRICS and schizophrenia.Biol Psychiatry. 2008 Jul 1;64(1):11-7. doi: 10.1016/j.biopsych.2008.03.003. Epub 2008 Apr 8. Biol Psychiatry. 2008. PMID: 18400207 Free PMC article.
-
Changes over time in frontotemporal activation during a working memory task in patients with schizophrenia.Schizophr Res. 2007 Mar;91(1-3):141-50. doi: 10.1016/j.schres.2006.12.001. Epub 2007 Jan 26. Schizophr Res. 2007. PMID: 17258892
Cited by
-
Glucose administration prior to a divided attention task improves tracking performance but not word recognition: evidence against differential memory enhancement?Psychopharmacology (Berl). 2009 Jan;202(1-3):549-58. doi: 10.1007/s00213-008-1387-1. Epub 2008 Nov 1. Psychopharmacology (Berl). 2009. PMID: 18979086 Clinical Trial.
-
Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically?: Results from the Changsha study.Asian J Psychiatr. 2012 Mar;5(1):73-82. doi: 10.1016/j.ajp.2011.12.001. Asian J Psychiatr. 2012. PMID: 22489255 Free PMC article. Clinical Trial.
-
Effects of individual glucose levels on the neuronal correlates of emotions.Front Hum Neurosci. 2013 May 21;7:212. doi: 10.3389/fnhum.2013.00212. eCollection 2013. Front Hum Neurosci. 2013. PMID: 23734117 Free PMC article.
-
Emotional memory in schizophrenia.Schizophr Bull. 2008 Sep;34(5):875-87. doi: 10.1093/schbul/sbn081. Epub 2008 Jul 15. Schizophr Bull. 2008. PMID: 18632728 Free PMC article. Review.
-
No effect of glucose administration in a novel contextual fear generalization protocol in rats.Transl Psychiatry. 2016 Sep 27;6(9):e903. doi: 10.1038/tp.2016.183. Transl Psychiatry. 2016. PMID: 27676444 Free PMC article.
References
-
- Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia. Am J Psychiatry. 1996;153:321–330. - PubMed
-
- Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26:119–136. - PubMed
-
- Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol Psychiatry. 2002;52:969–971. - PubMed
-
- Fujii DE, Wylie AM. Neurocognition and community outcome in schizophrenia: long-term predictive validity. Schizophr Res. 2002;59:219–223. - PubMed
-
- Sharma T, Antonova L. Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin North Am. 2003;26:25–40. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials